

Guillermo C. Artiles
Matthew A. Sklar
Omar A. Barentto
MCCARTER & ENGLISH, LLP
Four Gateway Center
100 Mulberry Street
Newark, NJ 07102
Tel: (973) 622-4444
Fax: 973.624.7070
gartiles@mccarter.com
msklar@mccarter.com
obarentto@mccarter.com

*Attorneys for Plaintiff
Neurocrine Biosciences, Inc.*

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF NEW JERSEY**

NEUROCRINE BIOSCIENCES, INC.

Plaintiff,

v.

ZYDUS PHARMACEUTICALS (USA) INC.,
ZYDUS WORLDWIDE DMCC, ZYDUS
HEALTHCARE (USA) LLC and ZYDUS
LIFESCIENCES LIMITED (f/k/a CADILA
HEALTHCARE LIMITED)

Defendants.

Civil Action No. _____

COMPLAINT FOR PATENT INFRINGEMENT

Neurocrine Biosciences, Inc. (“Neurocrine”), by way of Complaint against Defendants Zydus Pharmaceuticals (USA) Inc. (“Zydus Pharmaceuticals”), Zydus Worldwide DMCC (“Zydus Worldwide”), Zydus Healthcare (USA) LLC (“Zydus Healthcare”) and Zydus

Lifesciences Limited f/k/a Cadila Healthcare Limited (d/b/a Zydus Cadila) (“Zydus Lifesciences”) (collectively “Zydus” or “Defendants”), alleges as follows:

NATURE OF THE ACTION

1. This is a civil action for patent infringement of U.S. Patent No. 11,311,532 (“the ’532 patent” or “the patent-in-suit”), arising under the United States patent laws, Title 35, United States Code, § 100 *et. seq.*, including 35 U.S.C. §§ 271 and 281. This action relates to Zydus’ filing of an Abbreviated New Drug Application (“ANDA”) No. 216137 under Section 505(j) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 355(j), seeking U.S. Food and Drug Administration (“FDA”) approval to manufacture, use, import, offer to sell and/or sell Valbenazine Capsules, 40 mg, 60 mg and 80 mg (“Zydus’ generic products”) before the expiration of the patent-in-suit.

2. Neurocrine filed separate actions involving the same ANDA No. 216137 in this Court and the District of Delaware for patent infringement of U.S. Patent Nos. 10,065,952 (“the ’952 patent”), 10,844,058 (“the ’058 patent”), 10,851,103 (“the ’103 patent”), 10,851,104 (“the ’104 patent”), 10,857,137 (“the ’137 patent”), 10,857,148 (“the ’148 patent”), 10,874,648 (“the ’648 patent”), 10,906,902 (“the ’902 patent”), 10,906,903 (“the ’903 patent”), 10,912,771 (“the ’771 patent”), 10,919,892 (“the ’892 patent”), 10,940,141 (“the ’141 patent”) and 10,952,997 (“the ’997 patent”), (collectively “First Suit Patents”) in *Neurocrine Biosciences, Inc. v. Zydus Pharmaceuticals (USA) Inc. et al.*, C.A. No. 2:21-cv-14447-KM-JSA (D.N.J filed July 30, 2021) (“the First New Jersey Suit”) and *Neurocrine Biosciences, Inc. v. Zydus Pharmaceuticals (USA) Inc. et al.*, C.A. No. 1:21-cv-01118-MN (D. Del. filed July 30, 2021) (“the First Delaware Suit”), which on April 19, 2022 was consolidated in *Neurocrine Biosciences, Inc. v. Lupin Limited et al.*, No. 1:21-cv-01042-MN (D. Del.) (consolidated), (collectively “the First Suits”).

3. The First Suits were filed in response to a letter from Zydus dated June 15, 2021 (“Zydus’ First Notice Letter”), purporting to include an exhibit titled “Zydus’s Detailed Factual and Legal Bases in Support of its Paragraph IV Certification for Valbenazine Capsules, 40 mg and 80 mg.” Zydus’ First Notice Letter stated that Zydus had filed ANDA No. 216137, seeking approval to manufacture, use, import, offer to sell and/or sell Valbenazine Capsules, 40 mg and 80 mg before the expiration of the First Suit Patents. The First Suits included counts of infringement of the First Suit Patents.

4. The First New Jersey Suit was dismissed in favor of continued prosecution of the First Delaware Suit after Zydus Pharmaceuticals, Zydus Worldwide and Cadila Healthcare Limited answered that they would not contest subject matter jurisdiction, venue, or personal jurisdiction in Delaware for the alleged claims related to Zydus’ ANDA No. 216137 (*see* Notice of Voluntary Dismissal ordered in the First New Jersey Suit on March 22, 2022; *see also* Answer in the First Delaware Suit at ¶¶ 12-13, 15-16, 27, 30-31, and 33 (filed February 8, 2022)).

5. Neurocrine also filed separate actions involving the same ANDA No. 216137 in this Court and the District of Delaware for patent infringement of U.S. Patent Nos. 10,993,941 (“the ’941 patent”), 11,026,931 (“the ’931 patent”), 11,026,939 (“the ’939 patent”) and 11,040,029 (“the ’029 patent”) (collectively “Second Suit Patents”) in *Neurocrine Biosciences, Inc. v. Zydus Pharmaceuticals (USA) Inc. et al.*, C.A. No. 2:21-cv-19466-KM-JSA (D.N.J. filed October 29, 2021) (“the Second New Jersey Suit”) and *Neurocrine Biosciences, Inc. v. Zydus Pharmaceuticals (USA) Inc. et al.*, No. 1:21-cv-01553-MN (D. Del. filed October 29, 2021) (“the Second Delaware Suit”), which on April 19, 2022 was consolidated in *Neurocrine Biosciences, Inc. v. Lupin Limited et al.*, No. 1:21-cv-01042-MN (D. Del.) (consolidated) (collectively “the Second Suits”).

6. The Second Suits were filed in response to a letter from Zydus dated September 16, 2021 (“Zydus’ Second Notice Letter”), purporting to include an exhibit titled “Zydus’s Detailed Factual and Legal Bases in Support of its Paragraph IV Certification for Valbenazine Capsules, 40 mg and 80 mg.” Zydus’ Second Notice Letter stated that Zydus had filed ANDA No. 216137, seeking approval to manufacture, use, import, offer to sell and/or sell Valbenazine Capsules, 40 mg and 80 mg before the expiration of the Second Suit Patents. The Second Suits included counts of infringement of the Second Suit Patents.

7. The Second New Jersey Suit was dismissed in favor of continued prosecution of the Second Delaware Suit after Zydus Pharmaceuticals, Zydus Worldwide and Zydus Lifesciences f/k/a Cadila Healthcare Limited answered that they would not contest subject matter jurisdiction, venue, or personal jurisdiction in Delaware for the alleged claims related to Zydus’ ANDA No. 216137 (*see* Notice of Voluntary Dismissal ordered in the Second New Jersey Suit on March 22, 2022; *see also* Answer in the Second Delaware Suit at ¶¶ 15-16, 18-19, 22, 30, 33-34, and 36 (filed March 18, 2022)).

8. Neurocrine further filed separate actions involving the same ANDA No. 216137 in this Court and the District of Delaware for patent infringement of the ’952 patent, the ’058 patent, the ’103 patent, the ’104 patent, the ’137 patent, the ’148 patent, the ’648 patent, the ’902 patent, the ’903 patent, the ’771 patent, the ’892 patent, the ’141 patent, the ’997 patent, the ’941 patent, the ’931 patent, the ’939 patent and the ’029 patent (collectively “Third Suit Patents”), in *Neurocrine Biosciences, Inc. v. Zydus Pharmaceuticals (USA) Inc. et al.*, No. 1:22-cv-01882-CPO-EAP (D.N.J. filed April 1, 2022) (“the Third New Jersey Suit”) and *Neurocrine Biosciences, Inc. v. Zydus Pharmaceuticals (USA) Inc. et al.*, C.A. No. 1:22-cv-00439-MN (D. Del. filed April 1, 2022) (“the Third Delaware Suit”) (collectively “the Third Suits”).

9. The Third Suits were filed in response to a letter from Zydus dated February 18, 2022 (“Zydus’ Third Notice Letter”), purporting to include an exhibit titled “Zydus’s Detailed Factual and Legal Bases in Support of its Paragraph IV Certification for Valbenazine Capsules, 60 mg.” Zydus’ Third Notice Letter stated that Zydus had filed ANDA No. 216137, seeking approval to manufacture, use, import, offer to sell and/or sell Valbenazine Capsules, 60 mg before the expiration of the Third Suit Patents. The Third Suit included counts of infringement of the Third Suit Patents.

10. The Third New Jersey Suit was dismissed in favor of continued prosecution of the Third Delaware Suit after Zydus Pharmaceuticals, Zydus Worldwide and Zydus Lifesciences f/k/a Cadila Healthcare Limited answered that they would not contest subject matter jurisdiction, venue, or personal jurisdiction in Delaware for the alleged claims related to Zydus’ ANDA No. 216137 (*see* Notice of Voluntary Dismissal ordered in the Third New Jersey Suit on August 8, 2022; *see also* Answer in the Third Delaware Suit at ¶¶ 20-21, 23-24, 27, 35, 38-39, and 41 (filed August 1, 2022)).

11. This complaint is filed in response to a new, fourth letter from Zydus dated August 17, 2022 (“Zydus’ Fourth Notice Letter”), purporting to include an exhibit titled “Zydus’s Detailed Factual and Legal Bases in Support of its Paragraph IV Certification for Valbenazine Capsules, 40 mg, 60 mg, and 80mg.” Zydus’ Fourth Notice Letter stated that Zydus had filed ANDA No. 216137, seeking approval to manufacture, use, import, offer to sell and/or sell Zydus’ generic products before the expiration of the patent-in-suit.

THE PARTIES

12. Neurocrine is a corporation organized and existing under the laws of Delaware with its corporate headquarters at 12780 El Camino Real, San Diego, CA 92130.

13. Neurocrine is engaged in the business of researching, developing and bringing to market innovative pharmaceutical products for the treatment of neurological, endocrine and psychiatric disorders.

14. Upon information and belief, Zydus Pharmaceuticals is a corporation organized under the laws of New Jersey and its principal place of business is located at 73 Route 31 N., Pennington, New Jersey 08534.

15. Upon information and belief, Zydus Worldwide is a corporation organized under the laws of the United Arab Emirates and its principal place of business is located at Armada Tower 2, P2, Cluster P, 9 Floor, Office 908, Al Thanyah 5, Hadaeq Mohammed Bin Rashid, Dubai, United Arab Emirates.

16. Upon information and belief, Zydus Healthcare is a company organized under the laws of the state of Delaware and its principal place of business is located at 73 Route 31 N., Pennington, NJ, 08534-3601.

17. Upon information and belief, Zydus Lifesciences is a corporation organized under the laws of the Republic of India and its principal place of business is located at Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S.G. Highway, Ahmedabad, Gandhinagar GJ 382481 IN.

18. Upon information and belief, Zydus Lifesciences Limited was formerly known as Cadila Healthcare Limited. *See Neurocrine Biosciences, Inc. v. Zydus Pharmaceuticals (USA) Inc. et al*, C.A. No. 1:21-cv-01553-MN, D.I. Nos. 17-20 (D. Del. filed March 18, 2022) (Answer and Corporate Disclosure Statements filed by Zydus Pharmaceuticals, Zydus Worldwide, and Cadila Healthcare Limited stating that Zydus Lifesciences Limited was formerly known as Cadila Healthcare Limited). When the First Suits and Second Suits were filed, First Suit and Second Suit

Defendant Cadila Healthcare Limited was the company name associated with CIN L24230GJ1995PLC025878 and Registration Number 025878. As of the date of this filing, Zydus Lifesciences Limited is the company name associated with CIN L24230GJ1995PLC025878 and Registration Number 025878, and Zydus has identified this name change publicly. *See* <https://www.zyduslife.com/zyduslife/> (accessed September 30, 2022) (“Cadila Healthcare Ltd., is renamed as Zydus Lifesciences Ltd.”).

19. Upon information and belief, Zydus Pharmaceuticals is a subsidiary of Zydus Lifesciences.

20. Upon information and belief, Zydus Worldwide is a subsidiary of Zydus Lifesciences.

21. Upon information and belief, Zydus Healthcare is a subsidiary of Zydus Lifesciences.

JURISDICTION AND VENUE

22. This Court has subject matter jurisdiction under 28 U.S.C. §§ 1331 and 1338(a).

23. Plaintiff believes this case belongs in Delaware but is concurrently filing a case in this district out of an abundance of caution.

24. This Court has personal jurisdiction over Zydus Pharmaceuticals because, upon information and belief, Zydus Pharmaceuticals directly, or indirectly, develops, manufactures, markets and sells generic drugs throughout the United States and in this judicial district.

25. This Court has personal jurisdiction over Zydus Worldwide because, upon information and belief, Zydus Worldwide directly, or indirectly, develops, manufactures, markets and sells generic drugs throughout the United States and in this judicial district.

26. Upon information and belief, Zydus Worldwide is the holder of ANDA No. 216137.

27. This Court has personal jurisdiction over Zydus Healthcare because, upon information and belief, Zydus Healthcare directly, or indirectly, develops, manufactures, markets and sells generic drugs throughout the United States and in this judicial district.

28. This Court has personal jurisdiction over Zydus Lifesciences because, upon information and belief, Zydus Lifesciences directly, or indirectly, develops, manufactures, markets and sells generic drugs throughout the United States and in this judicial district.

29. Upon information and belief, Zydus Pharmaceuticals, Zydus Worldwide, Zydus Healthcare and Zydus Lifesciences hold themselves out as a unitary entity and operate as a single integrated business with respect to the regulatory approval, manufacturing, marketing, sale and distribution of generic pharmaceutical products throughout the United States, including in this judicial district.

30. Upon information and belief, Zydus Pharmaceuticals, Zydus Worldwide, Zydus Healthcare and Zydus Lifesciences have thus been, and continue to be, joint and prime actors in the drafting, submission, approval and maintenance of ANDA No. 216137.

31. For these reasons and for other reasons that will be presented to the Court if jurisdiction is challenged, the Court has personal jurisdiction over Zydus.

32. Venue is proper in this judicial district under 28 U.S.C. §§ 1391 and 1400(b), because Zydus Worldwide is incorporated in the United Arab Emirates and may be sued in any judicial district in the United States.

33. Venue is proper in this judicial district under 28 U.S.C. §§ 1391 and 1400(b), because Zydus Pharmaceuticals is incorporated in the state of New Jersey.

34. Venue is proper in this judicial district under 28 U.S.C. §§ 1391 and 1400(b), because, upon information and belief, Zydus Healthcare’s principal place of business is located in New Jersey.

35. Venue is proper in this judicial district under 28 U.S.C. §§ 1391 and 1400(b), because Zydus Lifesciences is incorporated in the Republic of India and may be sued in any judicial district in the United States.

FACTUAL BACKGROUND

The NDA

36. Neurocrine is the holder of New Drug Application (“NDA”) No. 209241 for INGREZZA[®] (valbenazine) Capsules in 40, 60, and 80 mg dosage forms (“INGREZZA[®] Capsules”).

37. The FDA approved NDA No. 209241 on April 11, 2017.

38. INGREZZA[®] Capsules are prescription drugs approved for the treatment of tardive dyskinesia. Valbenazine, which is present as the tosylate salt, is the active ingredient in INGREZZA[®] Capsules.

39. Valbenazine Capsules are marketed in the United States under the trademark INGREZZA[®].

The Patent-in-Suit

40. The United States Patent and Trademark Office (“the PTO”) issued the ’532 patent on April 26, 2022, titled “High Dosage Valbenazine Formulation and Compositions, Methods, and Kits Related Thereto.” A true and correct copy of the ’532 patent is attached as Exhibit A.

41. Neurocrine owns the ’532 patent through assignment as recorded by the PTO at Reel 054171, Frame 0426.

42. The '532 patent currently expires on September 18, 2038.

43. The '532 patent is listed in Approved Drug Products With Therapeutic Equivalence Evaluations ("the Orange Book") in connection with NDA No. 209241 for INGREZZA® Capsules.

The ANDA

44. Upon information and belief, Zydus submitted ANDA No. 216137 with the FDA under 21 U.S.C. § 355(j) seeking FDA approval to manufacture, use, import, offer to sell and/or sell in the United States Valbenazine Capsules, 40 mg, 60 mg and 80 mg (defined above as "Zydus' generic products"), which are generic versions of Neurocrine's INGREZZA® Capsules.

45. Zydus' Fourth Notice Letter states that ANDA No. 216137 contains certifications pursuant to 21 U.S.C. § 355(j)(2)(A)(vii)(IV), alleging that the claims of the patent-in-suit are invalid, unenforceable and/or will not be infringed by the manufacture, use, import, offer to sell and/or sale of Zydus' generic products.

46. Plaintiff commenced this action within 45 days of receiving Zydus' Fourth Notice Letter.

COUNT I

(INFRINGEMENT OF THE '532 PATENT)

47. Plaintiff realleges, and incorporates fully herein, each preceding paragraph.

48. Upon information and belief, Zydus filed ANDA No. 216137 seeking approval to manufacture, use, import, offer to sell and/or sell Zydus' generic products in the United States before the expiration of the '532 patent.

49. Zydus' Fourth Notice Letter states that Zydus filed with the FDA, pursuant to 21 U.S.C. § 355(j)(2)(A)(vii)(IV) and 21 C.F.R. § 314.94(a)(12)(i)(A)(4), a certification alleging that the claims of the '532 patent are invalid, unenforceable and/or will not be infringed.

50. Upon information and belief, in its ANDA No. 216137, Zydus has represented to the FDA that Zydus' generic products are pharmaceutically and therapeutically equivalent to Neurocrine's INGREZZA® Capsules.

51. Zydus has actual knowledge of the '532 patent, as evidenced by at least Zydus' Fourth Notice Letter.

52. Upon information and belief, under 35 U.S.C. § 271(e)(2)(A), Zydus has infringed at least one claim of the '532 patent by submitting, or causing to be submitted, to the FDA ANDA No. 216137, seeking approval to manufacture, use, import, offer to sell or sell Zydus' generic products before the expiration date of the '532 patent.

53. Upon information and belief, if ANDA No. 216137 is approved, Zydus intends to and will manufacture, use, import, offer to sell and/or sell Zydus' generic products in the United States.

54. Upon information and belief, if ANDA No. 216137 is approved, Zydus will infringe one or more claims of the '532 patent under § 271(a), either literally or under the doctrine of equivalents, by making, using, offering to sell, selling and/or importing Zydus' generic products, and/or by actively inducing infringement by others under § 271(b) and/or contributing to infringement under § 271(c), unless this Court orders that the effective date of any FDA approval of ANDA No. 216137 shall be no earlier than the expiration of the '532 patent.

55. Upon information and belief, Zydus knows, should know and intends that physicians will prescribe and patients will take Zydus' generic products for which approval is sought in ANDA No. 216137, and therefore will infringe at least one claim of the '532 patent.

56. Upon information and belief, Zydus has knowledge of the '532 patent and, by its proposed package insert for Zydus' generic products, knows or should know that it will induce

direct infringement of at least one claim of the '532 patent, either literally or under the doctrine of equivalents.

57. Upon information and belief, Zydus is aware and/or has knowledge that its proposed package insert will recommend, suggest, encourage and/or instruct others how to engage in an infringing use because healthcare professionals and/or patients will use Zydus' generic products according to the instructions in the proposed package insert in a way that directly infringes at least one claim of the '532 patent.

58. Upon information and belief, Zydus' actions relating to Zydus' ANDA No. 216137 complained of herein were done by and for the benefit of Zydus.

59. Plaintiff will be irreparably harmed by Zydus' infringing activities unless this Court enjoins those activities.

60. Plaintiff does not have an adequate remedy at law.

REQUEST FOR RELIEF

WHEREFORE, Plaintiff respectfully requests the following relief:

A. The entry of judgment under 35 U.S.C. § 271(e)(2)(A) that Zydus has infringed at least one claim of the '532 patent through Zydus' submission of ANDA No. 216137 to the FDA seeking approval to manufacture, use, import, offer to sell and/or sell Zydus' generic products in the United States before the expiration of the '532 patent;

B. The entry of judgment under 35 U.S.C. § 271(a), (b) and/or (c) that Zydus' making, using, offering to sell, selling or importing of Zydus' generic products before the expiration of the '532 patent will infringe, actively induce infringement and/or contribute to the infringement of at least one claim of the '532 patent under 35 U.S.C. § 271(a), (b) and/or (c);

C. The issuance of an order that the effective date of any FDA approval of Zydus' generic products shall be no earlier than the expiration date of the '532 patent and any additional periods of exclusivity, or any such later date as the Court may determine, in accordance with 35 U.S.C. § 271(e)(4)(A);

D. The entry of a preliminary and/or permanent injunction, enjoining Zydus and all persons acting in concert with Zydus from manufacturing, using, offering for sale or selling Zydus' generic products within the United States, or importing Zydus' generic products into the United States, until the expiration of the '532 patent, in accordance with 35 U.S.C. §§ 271(e)(4)(B) and 283;

E. The entry of a preliminary and/or permanent injunction, enjoining Zydus and all persons acting in concert with Zydus from seeking, obtaining or maintaining approval of the ANDA until the expiration of the '532 patent, in accordance with 35 U.S.C. §§ 271(e)(4)(B) and 283;

F. The issuance of a declaration that this is an exceptional case and an award to Plaintiff of their costs, expenses and disbursements in this action, including reasonable attorney fees, pursuant to 35 U.S.C. §§ 285 and 271(e)(4);

G. An award to Plaintiff of any further appropriate relief under 35 U.S.C. § 271(e)(4); and

H. An award to Plaintiff of any further and additional relief that this Court deems just and proper.

Respectfully submitted,

/s/ Guillermo C. Artiles

Guillermo C. Artiles

Matthew A. Sklar

Omar A. Barentto

MCCARTER & ENGLISH, LLP

Four Gateway Center

100 Mulberry Street

Newark, NJ 07102

Tel: (973) 622-4444

Fax: 973.624.7070

gartiles@mccarter.com

msklar@mccarter.com

obarentto@mccarter.com

Of Counsel:

James B. Monroe

Erin M. Sommers

Lauren J. Dowty

Jeanette M. Roorda

FINNEGAN, HENDERSON, FARABOW,

GARRETT & DUNNER, LLP

901 New York Avenue, NW

Washington, DC 20001-4431

(202) 408-4000

Dated: September 30, 2022

*Attorneys for Plaintiff Neurocrine
Biosciences, Inc.*